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Purpose: Few data exist to help physicians how to use diuretics in the acute heart failure setting, in order to provide the greatest symptomatic 
benefit with the least adverse effect and to select which subset of patients require a more aggressive diuretic strategy and monitorization. The aim 
of this study is to identify early predictors of diuretic response in a selected group of patients with acutely decompensated chronic heart failure 
(ADCHF).
Methods: Observational, prospective study including 100 patients admitted to a tertiary hospital with ADCHF.
Results: Mean ± standard deviation (SD) age was 76,0 ± 10,9 years. Sixty-one patients were female. Due to the persistence of congestive signs after 
three days of inpatient treatment, 16 (16%) patients maintained or increased i.v. furosemide dose during the study period - slow diuretic response 
(SDR) group. The other 84 patients had greater congestion relief and decreased i.v. furosemide dose or switched to oral furosemide - fast diuretic 
response (FDR) group. Admission day factors predicting SDR were: higher levels of pUr (mean ± SD, 69,6 ± 20,9 vs 52,5 ± 19,8, p = 0,002); higher 
levels of pUr / pCr ratio (mean ± SD, 58,3 ± 15,2 vs 49,6 ± 15,1, p = 0,036); higher levels of albuminuria (median [IQR], 131,5 [396,9] vs 47,1 [143,6], p 
= 0,011) – Figure 1; higher levels of RDW (median [IQR], 16,0 [1,9] vs 15,1 [1,5], p = 0,039); lower levels of HgB (mean ± SD, 11,5 ± 1,8 vs 12,6 ± 2,1, p 
= 0,04); and higher levels of hsTnT (median [IQR], 0,05 [0,05] vs 0,03 [0,03], p = 0,026) - Table. By multivariate analysis the strongest independent 
early predictors of SDR were: pUr (OR [95%CI], 1,04 [1,01 – 1,07], p = 0,006), and red-cell distribution width (RDW) (OR [95%CI], 1,47 [1,07 – 2,02], p = 
0,018). During the first three days of hospitalization the strongest independent factor associated with SDR was NTproBNP increase or decrease by 
less than 30% from day 1 to day 3 (OR [95%CI], 4,84 [1,14 – 20,55], p = 0,032) – Figure 2. Use of high dose spironolactone (50 to 100 mg/day) is 
associated with FDR (OR [95%CI], 0,17 [0,03 – 0,85], p = 0,031).
Figure 1. Comparison of Albuminuria (mg/g) in Slow versus Fast Diuretic Responders During The Initial 3 Days of Hospitalization.
Figure 2. Comparison of NTproBNP (pg/ml) in Slow versus Fast Diuretic Responders During The Initial 3 Days of Hospitalization. 
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Furosemide Maintenance or 
Increase
Furosemide Decrease or Oral 
Administration
p Value
IV Furosemide at Day 1 (mg) 72,5 ± 20,5 76,4 ± 21,8 0,51
pCr (mg/dL)
Day 1
Day 3
1,21 ± 0,28
1,40 ± 0,46
1,06 ± 0,28
1,1 ± 0,36
0,06
0,004
pUrea (mg/dL)
Day 1
Day 3
69,6 ± 20,9
79,7 ± 24,9
52,5 ± 19,8
59,0 ± 24,3
0,002
0,002
pUrea to pCr ratio
Day 1
Day 3
58,3 ± 15,2
58,8 ± 12,4
49,6 ± 15,1
54,3 ± 16,7
0,036
0,32
Albuminuria (mg/g)
Day 1
Day 3
131,5 [396,9]
123,9 [358,4]
47,1 [143,6]
26,4 [85,2]
0,011
0,001
HgB at Day 1 (g/dL) 11,5 ± 1,8 12,6 ± 2,1 0,04
RDW at Day 1 16,0 [1,9] 15,1 [1,5] 0,039
NTproBNP (pg/mL)
Day 1
Day 3
3390 [4511]
3013 [4116]
2698 [4577]
1701 [2563]
0,26
0,009
NTproBNP Decrease by Less than 30% or 
Increase from Day 1 to Day 3 – no. (%) 6 (37,5) 11 (13,1) 0,017
hsTnT (ng/mL)
Day 1
Day 3
0,05 [0,05]
0,06 [0,04]
0,03 [0,03]
0,03 [0,03]
0,026
0,004
Inpatients on Spironolactone – no. (%) 2 (12,5) 48 (57,1) 0,001
Inpatients on ACEi – no (%) 7 (43,8) 37 (44) 0,98
Inpatients on Beta-Blockers – no (%) 7 (43,8) 30 (35,7) 0,54
Time to Oral Furosemide (days) 5,9 ± 1,7 3,6 ± 2,2 <0,001
Hospital Length of Stay (days) 10,9 ± 3,2 8,5 ± 3,3 0,008
p = 0,011 p = 0,001
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Conclusions: High RDW and high levels of pUr at admission are strong predictors of SDR in ADCHF. No change or increase in NTproBNP in 
the first three days of inpatient treatment is associated with SDR. Spironolactone was associated with FDR in this study. Further studies 
are needed to explore the role of Spironolactone in this clinical setting.
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Table. Univariate Analysis for Furosemide Response Predictors, Furosemide Response Associations, Time to Oral Furosemide and Hospital 
Length of Stay.
